1
|
Frégeau-Proulx L, Lacouture A, Weidmann C, Jobin C, Audet-Walsh É. FACS-Free isolation and purification protocol of mouse prostate epithelial cells for organoid primary culture. MethodsX 2022; 9:101843. [PMID: 36147450 PMCID: PMC9486617 DOI: 10.1016/j.mex.2022.101843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Accepted: 08/29/2022] [Indexed: 11/17/2022] Open
Abstract
This protocol enables the generation of mouse prostate organoids without using flow cytometry, facilitating its implementation in most research laboratories. Usage of prostate organoids allows the study of complex in vivo phenotypes, beyond what can be done with immortalized cell lines.
The prostate is a gland that contributes to men's fertility. It is highly responsive to androgens and is often the site of carcinogenesis, as prostate cancer is the most frequent cancer in men in over a hundred countries. To study the normal prostate, few in vitro models exist, and most of them do not express the androgen receptor (AR). To overcome this issue, prostate epithelial cells can be grown in primary culture ex vivo in 2- and 3-dimensional culture (organoids). However, methods to purify these cells often require flow cytometry, thus necessitating specialized instruments and expertise. Herein, we present a detailed protocol for the harvest, purification, and primary culture of mouse prostate epithelial cells to grow prostate organoids ex vivo. This protocol does not require flow cytometry approaches, facilitating its implementation in most research laboratories, and organoids grown with this protocol are highly responsive to androgens. In summary, we present a new simple method that can be used to grow prostate organoids that recapitulate the androgen response of this gland in vivo.
Collapse
Affiliation(s)
- Lilianne Frégeau-Proulx
- Endocrinology - Nephrology Research Axis, CHU de Québec - Université Laval Research Center, Québec, QC, Canada.,Department of molecular medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada.,Centre de recherche sur le cancer de l'Université Laval, Québec, QC, Canada
| | - Aurélie Lacouture
- Endocrinology - Nephrology Research Axis, CHU de Québec - Université Laval Research Center, Québec, QC, Canada.,Department of molecular medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada.,Centre de recherche sur le cancer de l'Université Laval, Québec, QC, Canada
| | - Cindy Weidmann
- Endocrinology - Nephrology Research Axis, CHU de Québec - Université Laval Research Center, Québec, QC, Canada.,Centre de recherche sur le cancer de l'Université Laval, Québec, QC, Canada
| | - Cynthia Jobin
- Endocrinology - Nephrology Research Axis, CHU de Québec - Université Laval Research Center, Québec, QC, Canada.,Department of molecular medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada.,Centre de recherche sur le cancer de l'Université Laval, Québec, QC, Canada
| | - Étienne Audet-Walsh
- Endocrinology - Nephrology Research Axis, CHU de Québec - Université Laval Research Center, Québec, QC, Canada.,Department of molecular medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada.,Centre de recherche sur le cancer de l'Université Laval, Québec, QC, Canada
| |
Collapse
|